Anika Therapeutics, Inc. (NASDAQ: ANIK) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Anika Therapeutics, Inc. (NASDAQ: ANIK) had its price target lowered by analysts at Barrington Research from $37.00 to $25.00. They now have an "outperform" rating on the stock.
Anika Therapeutics Third Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics
Anika Reports Third Quarter 2024 Financial Results [Yahoo! Finance]